Evidence map›Paper›PMID 40593266›Full record

ArticleEndocrine2025

Current status, perceptions, and barriers regarding weight loss approaches in China.

Ziwei Lin, Hao Zhu, Si Si, Jiawei Xu, Esther Artime, Swarna Khare, Victoria Higgins, Andrea Leith, Yan Bi

Abstract read
In one paragraph

Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ziwei LinEli Lilly and Company, Suzhou, China.
Hao ZhuEli Lilly and Company, Suzhou, China.
Si SiEli Lilly and Company, Suzhou, China.
Jiawei XuEli Lilly and Company, Suzhou, China.
Esther ArtimeEli Lilly and Company, Alcobendas, Spain.
Swarna KhareEli Lilly and Company, Bracknell, UK.
Victoria HigginsAdelphi Real World, Bollington, UK.
Andrea LeithAdelphi Real World, Bollington, UK.
Yan BiNanjing Drum Tower Hospital affiliated to Nanjing University Medical School, Nanjing, China. biyan@nju.edu.cn.ORCID 0000-0003-3914-7854

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe management and barriers regarding weight loss in China. MATERIALS AND

methodsData were from the Adelphi Real World Obesity Disease Specific Programme™, a cross-sectional survey between April and July 2022 in Chinese clinical practice. Physicians managing people with obesity or overweight (PwO) and PwO aged ≥ 18 years, under weight management programs, and/or with a body mass index ≥ 28 kg/m

results100 physicians and 801 PwO were included. Before current clinical management, PwO had attempted self-management using their own diet (87%) and exercise (84%) programs, natural remedies/diet pills sold on the internet (26%) or over the counter diet pills (19%). Physicians reported that typical first-line weight management methods in clinical practice were diet (82%) and exercise (82%), with half (50%) using drug approaches. Only 19% of PwO reported full compliance with diet and exercise programs. Among the 78 physicians who used anti-obesity medications (AOMs), the single most important reason for initiating AOM was failure to reach the desired weight loss with diet and exercise alone (58%). Of the 78 physicians, 67% felt that most weight loss approaches always fail and 73% felt that AOM options were restricted; the top rated single most desired improvements in future AOMs were improved or greater efficacy (26%) and safer long-term use (26%). Of PwO, most (88%) had some willingness to try a new AOM.

conclusionPwO usually self-managed initial weight loss attempts. Physicians typically initiated lifestyle interventions as first-line treatment despite low PwO compliance. Both physicians and PwO desired improved AOMs. Of note, no approved prescription-only AOMs were available in China during the time window of the study.

Indexed as

ObesityOverweightPractice Patterns, Physicians'Weight LossWeight Reduction ProgramsAdultAnti-Obesity AgentsChinaCross-Sectional StudiesExerciseFemaleHumansMaleMiddle AgedAnti-Obesity AgentsChinaCross-sectionalObesityOverweightReal-world evidenceWeight control

Identifiers

PMID40593266
PMCPMC12464005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.